These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34181327)

  • 1. Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma.
    Bhatti ABHH; Naz K; Abbas G; Khan NY; Zia HH; Ahmed IN
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1731-1736. PubMed ID: 34181327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein.
    Cui R; He J; Zhang F; Wang B; Ding H; Shen H; Li Y; Chen X
    Br J Cancer; 2003 Jun; 88(12):1878-82. PubMed ID: 12799630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.
    Li H; Li T; Hu J; Liu J
    J Cancer Res Ther; 2021 Jul; 17(3):652-657. PubMed ID: 34269295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
    Kim Y; Park YH; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Lee SG
    Ann Transplant; 2016 Oct; 21():660-667. PubMed ID: 27777395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients.
    Hadi H; Wan Shuaib WMA; Raja Ali RA; Othman H
    Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
    Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
    Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
    Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.